Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Conditions: Breast Cancer Metastatic; Breast Cancer Interventions: Drug: Olaparib; Drug: Vorinostat Sponsors: Jenny C. Chang, MD; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials